Jazz Pharmaceuticals To Present Trial Data


Jazz Pharmaceuticals Inc. (Nasdaq: JAZZ) will present data from a Phase III clinical trial of its fibromyalgia treatment sodium oxybate. The stock price rocketed $2.85 to $3.87.


About this Entry

This page contains a single entry by published on June 10, 2009 9:51 AM.

Callaway Slashes Dividend was the previous entry in this blog.

Fitch Downgrades Colonial BancGroup's Rating is the next entry in this blog.

Find recent content on the main index or look in the archives to find all content.

Powered by Movable Type 5.12